Do the profits of the retail pharmacies booster.docVIP

 PAGE \* MERGEFORMAT 8 Do the profits of the retail pharmacies booster [Editor’s note] Recently, the issue of a joint-venture pharmaceutical companies ‘blocking’ of pharmacies around the parity were vigorous debates over the news, events, brand-name drugs once again reflects the delicate relationship with the retailers. Mr. Liu Guanzhong’s this column about this relationship from a supplier’s point of view expounded his views. [Case] Brand-name drugs and generic drug game, terminals and pharmaceutical companies win-win situation As rapid economic development manager of G-City area is very depressed lately Duan Yong, to the end of the city’s largest drugstore chain has introduced a so-called high B-margin products, while the B product and company flagship product is precisely A substitute relationship, A product cheaper prices than 20%. Although the product A product B in terms of the relative is definitely a best-selling brand, was originally expected under normal circumstances should not be voted out of generic drugs to intercept the terminal, but this year the chain drugstore devaluation B products display either location, it is recommended that the rate of A products have not been given full co-operation, resulting in sales and have a certain distance from same period last year. The face in the company rankings by sales, after completion rate, Duan Yong that time has had sleepless nights. In order to reverse the unfavorable situation, Duan Yong leadership at a higher level under the guidance of the market has done a full investigation and review, a detailed information about the negotiations was finally completed in the shortest possible time. Bibi A, B products, profit margins Duan Yong with information, in an appropriate time to find responsible for the chain pharmacy operations Manager Zhang, the two sides after the greeting, Duan Yong straight to the point, the two products A and B discussed the relationship between product market competition up. A